- A new report provides an overview of the global clinical trial landscape for cerebral palsy, including trial numbers and enrollment trends. - The review covers clinical trials by region, country (G7 & E7), phase, trial status, endpoint status, and sponsor type. - The report identifies prominent drugs in ongoing trials and key companies involved in cerebral palsy therapeutics. - It also analyzes unaccomplished trials and enrollment trends over the past five years, offering insights for strategic decision-making.

Dec 31, 2024

返回机构列表

Medytox Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（4）

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines and Lateral Canthal Lines

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines and Lateral Canthal Lines

Healthy Volunteer Study to Determine the Safety and Tolerability of MT10109 (Clostridium Botulinum Toxin Type A) in Comparison to Botox(Registered Trademark)

A Phase 3, Multicenter, Double-blind, Randomized, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines in Japanese Adults

药物批准

按机构分类的批准

近期批准

资讯

Global Cerebral Palsy Clinical Trial Landscape Assessed in New 2024 Review